Fig. 1
From: Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies
Schematic representation of TCE and NKCE formats approved or in clinical development for hematological malignancies. Five of them are marketed as of July 2023: blinatumomab (Blincyto®), mosunetuzumab (Lunsumio®), teclistamab (Tecvayli®), epcoritamab (Epkinly®) and glofitamab (Columvi®). Additionally, elranatamab and talquetamab are under review, and odronextamab and linvoseltamab are in late-stage clinical trials